Author: Tan, Zhaoli; Gao, Lihua; Wang, Yan; Yin, Huihui; Xi, Yongyi; Wu, Xiaojie; Shao, Yong; Qiu, Weiyi; Du, Peng; Shen, Wenlong; Fu, Ling; Jia, Ru; Zhao, Chuanhua; Zhang, Yun; Zhao, Zhihu; Sun, Zhiwei; Chen, Hongxing; Hu, Xianwen; Xu, Jianming; Wang, Youliang
Title: PRSS contributes to cetuximab resistance in colorectal cancer Document date: 2020_1_1
ID: tymoeyoo_38
Snippet: Targeted mAbs, including cetuximab and bevacizumab, effectively prolong survival in patients with cancer and have become a standard component of therapy for patients with mCRC. Nevertheless, major obstacles to antibody therapy include the lack of secreted response biomarkers and primary/secondary resistance to these mAbs. Previous data have shown that mCRC lesions harboring KRAS and BRAF mutations are highly associated with a poor prognosis and p.....
Document: Targeted mAbs, including cetuximab and bevacizumab, effectively prolong survival in patients with cancer and have become a standard component of therapy for patients with mCRC. Nevertheless, major obstacles to antibody therapy include the lack of secreted response biomarkers and primary/secondary resistance to these mAbs. Previous data have shown that mCRC lesions harboring KRAS and BRAF mutations are highly associated with a poor prognosis and poor objective response to cetuximab therapy (15, 33) . Therefore, investigation of the mechanism of mAb resistance and identification of useful biomarkers for mAb therapy may guide treatment selection and have a significant clinical impact and are greatly warranted. The present work aimed to characterize the PRSS secretion involved in the response and resistance to cetuximab therapy and to exploit PRSS for biomarker discovery.
Search related documents:
Co phrase search for related documents- antibody therapy and cancer patient: 1
- antibody therapy and cetuximab therapy: 1
- antibody therapy and clinical impact: 1, 2, 3
- antibody therapy and mAb resistance: 1
- antibody therapy and mAb therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- antibody therapy and objective response: 1, 2
- antibody therapy and poor prognosis: 1, 2, 3
- antibody therapy and present work: 1
- antibody therapy and response biomarker: 1
- antibody therapy and significant clinical impact: 1
- bevacizumab cetuximab and cetuximab therapy: 1, 2, 3, 4, 5
- bevacizumab cetuximab and mAb resistance: 1
- bevacizumab cetuximab and poor prognosis: 1, 2
- bevacizumab cetuximab and primary secondary resistance: 1
- bevacizumab cetuximab and resistance response: 1, 2
- bevacizumab cetuximab and response biomarker: 1
- biomarker discovery and clinical impact: 1
- biomarker discovery and poor prognosis: 1
- biomarker discovery and response biomarker: 1
Co phrase search for related documents, hyperlinks ordered by date